

PHARMACY AND THERAPEUTICS COMMITTEE

The purpose of the P&T is to evaluate available evidence regarding the relative safety, efficacy/effectiveness of prescription drugs within a class or classes and make recommendations to PharmPix and/or its clients to create and manage formularies. In its evaluation, the P&T reviews the most current available data of well-designed studies, clinical guidelines and/or recommendations of recognized medical organizations.

PharmPix's P&T is a review committee appointed by PharmPix, and is integrated by Board Certified Specialists and Clinical Pharmacists who are experts in diseases, drugs, and treatment protocols. The objectives of this committee are:

- a) Evaluate, analyze and recommend treatment protocols and procedures for the timely use of and access to both formulary and non-formulary drug products at least annually.
- b) Establish procedures to evaluate evidence-based reviews of prescriptions drug classes to assist in the formation of recommendations to PharmPix and/or its clients' formularies.
- c) Consider and recommend action on independent evidence-based reviews of drug classes. This review must consider safety and efficacy/effectiveness available at the time of the review. All analysis, evidence and references brought to the committee, by PharmPix's formulary management pharmacists, for review shall be the result of a rigorous assessment of the scientific evidence.
- d) Recommendations made by the P&T will be based just on clinical evidence, not on economic considerations. The cost and economic impact analysis will be performed by PharmPix's formulary management personnel. Thus, based on the clinical advantages or disadvantages, the P&T will categorize the drugs in one of the below categories:
 - i. F - on Formulary, no restrictions
 - ii. PA - on formulary with Prior Authorization criteria
 - iii. ST - on formulary with Step-Therapy criteria
 - iv. MD - on formulary, reserved for specific provider specialties

- v. QL - on formulary with a specific quantity limit
- vi. AGE - on formulary, reserved for specific age groups
- vii. M - may be available
- viii. NF - not on formulary

If the drug is considered “F, PA, ST, MD, QL, or AGE”, the medication will be added to the formulary no matter the economic impact. If the drug is considered “NF”, the medication will not be added to the formulary. If the drug is considered “M”, PharmPix or the client’s formulary management team will make the decision based on economic considerations (pharmacoeconomic studies).

- e) Identify the most clinically effective ways and recommend performing utilization management strategies like prior authorization, step therapy, regimen optimization, etc.
- f) Develop protocols and procedures for the use of and access to non-formulary drug products.
- g) Establish policies and procedures to educate and inform health care providers about drug products, usage, and committee decisions.
- h) Review the Drug Formularies and therapeutic classes at least annually.
- i) Review Utilization Management Programs annually.
- j) Support educational programs promoting appropriate drug use.